|
Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors. |
|
|
Research Funding - Bayer (Inst); Novartis (Inst); SERVIER (Inst) |
Expert Testimony - Amgen; BioSim; Merck; Sanofi |
|
|
|
Stock and Other Ownership Interests - Faron Pharmaceuticals; Orion; Sartar Therapeutics |
Consulting or Advisory Role - Orion |
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Sharp & Dohme; Novartis; Roche; Takeda |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - CytomX Therapeutics; Novartis |
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Bristol-Myers Squibb; EMD Serono; Healios; Immune Cell Therapy (I); Incyte; Karyopharm Therapeutics; MedImmune; Merck; NCI; Novartis; Regeneron |
Travel, Accommodations, Expenses - ARMO BioSciences |
|
|
Consulting or Advisory Role - BeiGene; Samyang |
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
|
|
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche/Genentech |
Research Funding - Novartis (Inst); Roche (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Dana-Farber Cancer Institute |
Consulting or Advisory Role - Amgen; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis |
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst) |
Patents, Royalties, Other Intellectual Property - patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis |
Other Relationship - Bristol-Myers Squibb; Genentech/Roche |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
|
Travel, Accommodations, Expenses - Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
Patents, Royalties, Other Intellectual Property - Novartis |
|
|
Consulting or Advisory Role - Amgen; Bayer; Lilly; Merck Serono; Novartis; Roche/Genentech; SERVIER; Takeda |
Speakers' Bureau - Merck Serono; Roche; SERVIER |
Research Funding - Johnson & Johnson (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst); Theradex (Inst) |
Travel, Accommodations, Expenses - Roche |